3/26
05:49 am
bntx
BioNTech (BNTX) was upgraded by Truist Financial Corporation to "strong-buy".
Low
Report
BioNTech (BNTX) was upgraded by Truist Financial Corporation to "strong-buy".
3/25
09:17 am
bntx
BioNTech (BNTX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Low
Report
BioNTech (BNTX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
3/24
07:43 am
bntx
BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer [Yahoo! Finance]
Low
Report
BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer [Yahoo! Finance]
3/24
06:45 am
bntx
BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
Low
Report
BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
3/17
09:17 am
bntx
BioNTech (BNTX) had its "buy" rating reaffirmed by Deutsche Bank Aktiengesellschaft.
Medium
Report
BioNTech (BNTX) had its "buy" rating reaffirmed by Deutsche Bank Aktiengesellschaft.
3/11
12:53 pm
bntx
BioNTech (BNTX) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $171.00 price target on the stock.
Low
Report
BioNTech (BNTX) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $171.00 price target on the stock.
3/11
12:29 pm
bntx
BioNTech (BNTX) had its price target lowered by Citigroup Inc. from $145.00 to $130.00. They now have a "buy" rating on the stock.
Low
Report
BioNTech (BNTX) had its price target lowered by Citigroup Inc. from $145.00 to $130.00. They now have a "buy" rating on the stock.
3/11
10:56 am
bntx
BioNTech (BNTX) had its price target lowered by TD Cowen from $116.00 to $94.00. They now have a "hold" rating on the stock.
Low
Report
BioNTech (BNTX) had its price target lowered by TD Cowen from $116.00 to $94.00. They now have a "hold" rating on the stock.
3/11
10:19 am
bntx
BioNTech (BNTX) had its price target lowered by BMO Capital Markets from $143.00 to $128.00. They now have an "outperform" rating on the stock.
Low
Report
BioNTech (BNTX) had its price target lowered by BMO Capital Markets from $143.00 to $128.00. They now have an "outperform" rating on the stock.
3/11
09:19 am
bntx
BioNTech (BNTX) had its "buy" rating reaffirmed by The Goldman Sachs Group, Inc..
Medium
Report
BioNTech (BNTX) had its "buy" rating reaffirmed by The Goldman Sachs Group, Inc..
3/10
07:01 pm
bntx
BioNTech (BNTX) was given a new $155.00 price target by Truist Financial Corporation.
Medium
Report
BioNTech (BNTX) was given a new $155.00 price target by Truist Financial Corporation.
3/10
05:04 pm
bntx
BioNTech (BNTX) had its "outperform" rating reaffirmed by Raymond James Financial, Inc..
Medium
Report
BioNTech (BNTX) had its "outperform" rating reaffirmed by Raymond James Financial, Inc..
3/10
04:18 pm
bntx
BioNTech (BNTX) had its price target lowered by Jefferies Financial Group Inc. from $151.00 to $138.00. They now have a "buy" rating on the stock.
Medium
Report
BioNTech (BNTX) had its price target lowered by Jefferies Financial Group Inc. from $151.00 to $138.00. They now have a "buy" rating on the stock.
3/10
03:12 pm
bntx
BioNTech SE (BNTX) Q4 2025 Earnings Call Highlights: Strategic Advances Amidst Revenue Challenges [Yahoo! Finance]
Low
Report
BioNTech SE (BNTX) Q4 2025 Earnings Call Highlights: Strategic Advances Amidst Revenue Challenges [Yahoo! Finance]
3/10
03:02 pm
bntx
BioNTech (BNTX) had its "overweight" rating reaffirmed by Morgan Stanley.
Low
Report
BioNTech (BNTX) had its "overweight" rating reaffirmed by Morgan Stanley.
3/10
03:02 pm
bntx
BioNTech (BNTX) had its "buy" rating reaffirmed by Bank of America Corporation.
Low
Report
BioNTech (BNTX) had its "buy" rating reaffirmed by Bank of America Corporation.
3/10
02:48 pm
bntx
BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Low
Report
BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
3/10
12:21 pm
bntx
Why BioNTech Stock Is Getting Crushed Today [Yahoo! Finance]
Medium
Report
Why BioNTech Stock Is Getting Crushed Today [Yahoo! Finance]
3/10
12:00 pm
bntx
BioNTech co-founders set to launch new mRNA venture as company sharpens oncology focus [Yahoo! Finance]
Low
Report
BioNTech co-founders set to launch new mRNA venture as company sharpens oncology focus [Yahoo! Finance]
3/10
07:11 am
bntx
BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update [Yahoo! Finance]
Low
Report
BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update [Yahoo! Finance]
3/10
07:11 am
bntx
BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030 [Yahoo! Finance]
Low
Report
BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030 [Yahoo! Finance]
3/10
06:45 am
bntx
BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
Medium
Report
BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
3/10
06:33 am
bntx
BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
High
Report
BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
2/25
09:00 am
bntx
Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026
Low
Report
Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026
2/24
06:45 am
bntx
BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026
Low
Report
BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026